Alpha2-adrenergic agonists for the management of opioid withdrawal

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Gowing, Linda ^a   Farrell, Michael ^b   Ali, Robert ^a   White, Jason M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute disease; Adrenergic alpha agonists *therapeutic use ; Controlled clinical trials as topic; Humans; Methadone therapeutic use ; Narcotics therapeutic use ; Randomized controlled trials as topic; Receptors, adrenergic, alpha 2 *agonists ; Substance withdrawal syndrome *rehabilitation

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUPRENORPHINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CHLORPROTHIXENE; CLONIDINE; CLORAZEPATE; DIAZEPAM; DIURETIC AGENT; FLUNITRAZEPAM; GUANFACINE; LEFETAMINE; LEVOMEPROMAZINE; LOFEXIDINE; LOPERAMIDE; LORAZEPAM; METHADONE; METOCLOPRAMIDE; MIANSERIN; NALOXONE; NALTREXONE; PARACETAMOL; PLACEBO; TIZANIDINE; TOLPERISONE; TRIHEXYPHENIDYL; UNINDEXED DRUG; ZOLPIDEM;

ASTHENIA; BLOOD PRESSURE; CLINICAL TRIAL; COCHRANE LIBRARY; DEHYDRATION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMBASE; ENERGY; EXTRAPYRAMIDAL SYMPTOM; FLUID THERAPY; HEART RATE; HEROIN DEPENDENCE; HUMAN; HYPOTENSION; INSOMNIA; LOADING DRUG DOSE; MEAN ARTERIAL PRESSURE; MEDLINE; META ANALYSIS; METHADONE TREATMENT; OPIATE ADDICTION; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRESCRIPTION; REVIEW; SEDATION; SIDE EFFECT; SYMPTOM; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 69949099514     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002024.pub3     Document Type: Review

References (98)

1. * Batey R, Liddle C, Craig P. A placebo controlled trial of clonidine in the outpatient management of heroin withdrawal. Australian Drug and Alcohol Review 1987;6(1):11-14
2. * Bearn J, Gossop M, Strang J. Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug and Alcohol Dependence 1996;43(1-2):87-91.
3. * Bearn J, Gossop M, Strang J. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug and Alcohol Dependence 1998;50:227-232
4. * Benos VJ. Clonidine in opiate withdrawal syndrome [Clonidin beim opiatentzugssyndrom]. Fortschritte der Medizin 1985;103(42): 991-995
5. * Bertschy G, Bryois C, Bondolfi G, Velardi A, Budry P, Dascal D, et al.The association carbamazepine-mianserin in opiate withdrawal: a double blind pilot study versus clonidine. Pharmacological Research 1997;35(5):451-456
6. * Camí J, de Torres S, San L, Solé À, Guerra D, Ugena B. Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin. Clinical Pharmacology and Therapeutics 1985; 38(3):336-341
7. * Carnwath T, Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug and Alcohol Dependence 1998;50(3):251-254
8. * Gerra G, Marcato A, Caccavari R, Fontanesi B, Delsignore R, Fertonani G, et al.Clonidine and opiate receptor antagonists in the treatment of heroin addiction. Journal of Substance Abuse Treatment 1995;12(1):35-41.
9. Gerra G, Zaimovic A, Rustichelli P, Fontanesi B, Zambelli U, Timpano M, et al.Rapid opiate detoxification in outpatient treatment: Relationship with naltrexone compliance. Journal of Substance Abuse Treatment 2000;18(1):185-191 (Pubitemid 30123102)
10. * Gupta AK, Jha BK. Clonidine in heroin withdrawal syndrome: A controlled study in India. British Journal of Addiction 1988;83(9): 1079-1084
11. Howells C, Allen S, Gupta J, Farrell M. A double blind study comparing the efficacy of methadone and lofexidine in the treatment of opiate detoxification in prisoners at HMP Winchester. Britannia Pharmaceuticals Ltd 1999.
12. * Howells C, Allen S, Gupta J, Stillwell G, Marsden J, Farrell M. Prison based detoxification for opioid dependence: A randomised double blind controlled trial of lofexidine andmethadone. Drug and Alcohol Dependence 2002;67(2):169-176
13. * Jiang Z. Rapid detoxification with clonidine for heroin addiction: A comparative study on its efficacy vs methadone [[Chinese]]. Chinese Journal of Neurology and Psychiatry 1993;26(1):10-13
14. * Kahn A, Mumford JP, Rogers GA, Beckford H. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug and Alcohol Dependence 10-1-1997;44(1):57-61.
15. * Kleber HD, Riordan CE, Rounsaville B, Kosten T, Charney D, Gaspari J, et al.Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry 1985;42(4):391-394
16. Kosten TR, Rounsaville BJ, Kleber HD. Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse 1985; 11(1-2):1-10.
17. Kosten TR, Rounsaville BJ, Kleber HD. Relationship of depression to clonidine detoxification of opiate addicts. Comprehensive Psychiatry 1984;25(5):503-508 (Pubitemid 14009296)
18. Rounsaville BJ, Kosten T, Kleber H. Success and failure at outpatient opioid detoxification: Evaluating the process of clonidine and methadone assisted withdrawal. Journal of Nervous and Mental Disease 1985;173(2):103-110 (Pubitemid 15131519)
19. Li M, Chen K, Mo Z. Use of qigong therapy in the detoxification of heroin addicts. Alternative Therapies in Health and Medicine 2002;8 (1):50-59 (Pubitemid 34052987)
20. * Lin S-K, Strang J, Su L-W, Tsai C-J, Hu W-H. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug and Alcohol Dependence 1997;48 (2):127-133
21. Cami J, Gilabert M, San L, de la Torre R. Hypercortisolism after opioid discontinuation in rapid detoxification of heroin addicts. British Journal of Addiction 1992;87(8):1145-1151
22. * San L, Camí J, Peri JM, Mata R, Porta M. Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. British Journal of Addiction 1990;85 (1):141-147
23. San L, Peri JM, Mata R, Porta M. Success and failure at inpatient heroin detoxification. British Journal of Addiction 1989;84(1):81-87 (Pubitemid 19071335)
24. * San L, Fernández T, Camí J, Gossop M. Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin-addicted patients. Journal of Substance Abuse Treatment 1994;11(5): 463-469
25. * Senay E, Tennant FS, Washton AM. [Boehringer Ingelheim GmbH report number U85-0844]. Boehringer Ingelheim Pty Ltd 1983.
26. Sos I, Kiss N, Csorba J, Gerevich J. Tizanidine in the treatment of acute withdrawal symptoms in heroin dependent patients [A tizanidin hatekonysaga heroinfuggo betegek akut megvonasi tuneteinek kezeleseben]. Orvosi Hetilap 2000;141(15):783-786
27. Umbricht A, Hoover DR, Tucker MJ, Leslie JM, Chaisson RE, Preston KL. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug and Alcohol Dependence 2003;69(3):263-272 (Pubitemid 36293938)
28. Vilalta J, Treserra J, Garcia-Esteve L, Garcia-Giralt M, Cirera E. Methadone, clonidine and levomepromazine in the treatment of opiate abstinence syndrome: double-blind clinical trial in heroin-addicted patients admitted to a general hospital for organic pathology. [Metadona, clonidina y levomepromacina en el tratamiento del sindrome de abstinencia a opiaceos: ensayo clinico a doble ciego en pacientes heroinomanos ingresados por patologia organica en un hospital general.]. Medicina Clinica 1987;88(17):674-676 [MEDLINE: 87285711]
29. Washton AM, Resnick RB. Clonidine versus methadone for opiate detoxification. Lancet 13-12-1980;2(8207):1297.
30. * Washton AM, Resnick RB. Clonidine vs methadone for opiate detoxification: double-blind outpatient trials. In: Harris LS editor (s). Problems of Drug Dependence, 1980. Proceedings of the 42nd An- nual Scientific Meeting, The Committee on Problems of Drug Depen- dence, Inc. Washington D.C.: Department of Health and Human Services, 1981.
31. Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, et al.A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug and Alcohol Dependence 2008;97:158-168
32. * Akhondzadeh S, Ahmadi-Abhari SA, Assadi SM, Shabestari OL, Kashani AR, Farzanehgan ZM. Double-blind randomised controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. Journal of Clinical Pharmacy and Therapeutics 2000;25(5):347-353
33. * Batey R. Outpatient detoxification in heroin users - a comparison of a hemineurin and a clonidine regime. Australian Alcohol/Drug Review 1985;4(1):53-55
34. Beswick T, Best D, Rees S, Bearn J, Gossop M, Strang J. Major disruptions of sleep during treatment of the opiate withdrawal syndrome: differences betweenmethadone and lofexidine detoxification treatments. Addiction Biology 2003;8:49-57. (Pubitemid 36433980)
35. Beswick T, Best D, Bearn J, Gossop M, Rees S, Strang J. The effectiveness of combined naloxone/lofexidine in opiate detoxification: results from a double-blind randomized and placebo-controlled trial. Am J Addict 2003;12(4):295-305. (Pubitemid 37175522)
36. * Casey PR, Tomiak RHH. Clonidine in opiate withdrawal. Boehringer Ingelheim Ltd 1988.
37. * Charney DS, Sternberg DE, Kleber HD, Heninger GR, Redmond DE. The clinical use of clonidine in abrupt withdrawal from methadone. Archives of General Psychiatry 1981;38(11):1273-1277 [MEDLINE: 82067233]
38. * Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug and Alcohol Dependence 1994;36(2):115-121 [MEDLINE: 95154178]
39. * Gerra G, Zaimovic A, Giusti F, Di Gennaro C, Zambelli U, et al.Lofexidine versus clonidine in rapid opiate detoxification. Journal of Substance Abuse Treatment 2001;21(1):11-17 [: EMBASE 2001291795]
40. * Gold MS, Redmond DE, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 1978;2(8090):599-600. [MEDLINE: 79009448]
41. * Gold MS, Redmond DE, Kleber HD. Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal. American Journal of Psychiatry 1979;136(1):100-102 [MEDLINE: 79080422]
42. * Gold MS, Pottash ALC, Sweeney DR, Kleber HD. Effect of methadone dosage on clonidine detoxification efficacy. American Journal of Psychiatry 1980;137(3):375-6. [MEDLINE: 80127773]
43. Gold MS, Pottash ALC, Extein I, Stoll A. Clinical utility of clonidine in opiate withdrawal. In: Harris LS editor(s). Problems of Drug Dependence, 1980. Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Washington, D.C.: Department of Health and Human Services, 1981.
44. * Hartmann F, Poirier M-F, Bourdel M-C, Loo H, LeComte J-M, Schwartz J-C. Comparison of Acetophen with clonidine for opiate withdrawal symptoms. American Journal of Psychiatry 1991;148(5): 627-629 [MEDLINE: 91206611]
45. * Huertas D, Lopez-Gomez I, Chamorro L, Martin M. A new combined treatment for opioid detoxification: The association between dextropropoxyphene and guanfacine [Nueva pauta combinada para la desintoxicacion de opiaceos: la linea DG]. Revista de Psiquiatria de la Facultad de Medicina de Barcelona 1995;22(5):109-113 [: PsycINFO 1996-86268-001.]
46. * Janiri L, Mannelli P, Persico AM, Serretti A, Tempesta E. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug and Alcohol Dependence 1994; 36(2):139-145 [MEDLINE: 95154181]
47. * Jasinksi DR, Johnson RE, Kocher TR. Clonidine in morphine withdrawal: differential effects on signs and symptoms. Archives of General Psychiatry 1985;42(11):1063-1066 [MEDLINE: Medline 86024669]
48. Jimenez-Lerma JM, Landabaso M, Iraurgi I, Calle R, Sanz J, Gutierrez-Fraile M. Nimodipine in opiate detoxification: A controlled trial. Addiction 2002;97(7):819-824
49. * Kasvikis Y, Bradley B, Gossop M, Griffiths P, Marks I. Clonidine versus long and short termmethadone aided withdrawal fromopiates: An uncontrolled comparison. International Journal of the Addictions 1990;25(10):1169-1178 [MEDLINE: 91216677]
50. Malhotra A, Basu D, Chintalapudi M, Mattoo SK, Varma VK. Clonidine versus withdrawal using an opioid in in-patient opioid detoxification. European Addiction Research 1997;3:146-149
51. McCambridge J, Gossop M, Beswick T, Best D, Bearn J, Rees S, et al.In-patient detoxification procedures, treatment retention, and post-treatment opiate use: Comparison of lofexidine+naloxone, lofexidine+placebo, and methadone. Drug & Alcohol Dependence 2007;88(1):91-95 (Pubitemid 46420402)
52. * Muga R, Tor J, Forteza-Rei J, Jacas C, Altes J, Mestre L. Comparative effectiveness of alpha-2 adrenergic agonists (clonidine and guanfacine) in the hospital detoxification of opiate addicts [Eficacia comparada de agonistas alpha2-adrenergicos (clonidina-guanfacina) en la desintoxicacion hospitalaria de adictos a opiaceos]. Medicina Clinica 1990;94(5):169-172 [MEDLINE: 90220032]
53. * Myles J, Law F, Raybould T. A double-blind randomised controlled trial of buprenorphine/naloxone (suboxone) versus methadone/ lofexidine for the detoxification of opiate-dependent addicts. Drug and Alcohol Dependence 2000;60(Suppl 1):156.
54. O'Connor PG, Waugh ME, Carroll KM, Rounsaville BJ, Diakogiannis IA, Schottenfeld RS. Primary care-based ambulatory opioid detoxification: the results of a clinical trial. Journal of General Internal Medicine 1995;10(5):255-260 [MEDLINE: 95341424]
55. O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting. A randomised trial. Annals of Internal Medicine 1997; 127(7):526-530 [MEDLINE: 97443112]
56. * Pini LA, Sternieri E, Ferretti C. Dapiprazole compared with clonidine and a placebo in detoxification of opiate addicts. International Journal of Clinical Pharmacology Research 1991;11(2):99-105. [MEDLINE: 91348968]
57. * Rawson RA, Washton AM, Resnick RB, Tennant Jr FS. Clonidine hydrochloride detoxification from methadone treatment - the value of naltrexone aftercare. Advances in Alcohol and Substance Abuse 1984; 3(3):41-49 [MEDLINE: 85043337]
58. Satija DC, Natani GD, Purohit DR, Gaur R, Bhati GS. A double blind comparative study of usefulness of clonidine and symptomatic therapy in opiate detoxification. Indian Journal of Psychiatry 1988; 30(1):55-59 [: PsycINFO 1991-55875-001]
59. * Stanhope JM, Curry KH, Nayer R. Heroin dependence: inpatient detoxification with clonidine. Australian Alcohol/Drug Review 1985; 4(1):56-61.
60. * Strang J, Marks I, Dawe S, Powell J,Gossop M, Richards D, Gray J. Type of hospital setting and treatment outcome with heroin addicts. Results from a randomised trial. British Journal of Psychiatry 1997; 171:335-339 [MEDLINE: 98040752]
61. * Täschner K-L. A controlled comparison of clonidine and doxepin in the treatment of the opiate withdrawal syndrome. Pharmacopsychiatry 1986;19(3):91-95 [MEDLINE: 86260145]
62. Telias D, Nir-Hod J. Buprenorphine-ketorolac vs. clonidinenaproxen in the withdrawal from opioids. International Journal of Psychosocial Rehabilitation 2000;4(4):441-6.
63. Washton AM, Resnick RB, LaPlace RW. Clonidine hydrochloride: a non opiate treatment for opiate withdrawal. Psychopharmacology Bulletin 1980;16(2):50-52
64. * White R, Alcorn R, Feinmann C. Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine. Drug& Alcohol Dependence 2001;65(1):77-83.
65. * Wilson RS, diGeorge WS. Methadone combined with clonidine versus clonidine alone in opiate detoxification. Journal of Substance Abuse Treatment 1993;10(6):529-535 [MEDLINE: 94141976]
66. *Wylie AS, Stewart AM. Lofexidine based regimen for opiate addicts. British Journal of General Practice 1995;45(393):217-218 [MEDLINE: 95336788]
67. Akhurst JS. The use of lofexidine by drug dependency units in the United Kingdom. European Addiction Research 1999;5:43-49. [MEDLINE: 99187427]
68. Amato L, Davoli M, Ferri M, Ali R. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858]
69. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD005031.pub2]
70. Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug and Alcohol Dependence 2000;58(1):85-92.
71. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. Available from www.cochrane-handbook.org. The Cochrane Collaboration, [updated February 2008].
72. Day E, Ison J, Strang J. Inpatient versus other settings for detoxification for opioid dependence. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD004580.pub2]
73. Farrell M. Opiate withdrawal. Addiction 1994;89(11):1471-1475 [MEDLINE: 95144010]
74. Gold MS, Pottash AC. The neurobiological implications of clonidine HCl. Annals of the New York Academy of Science 1989;362:191-202.
75. Gorceix A, Dugarin J, Pommier F. Use of presynaptic alpha-mimetics for withdrawal in heroin addicts [Utilisation des alpha-mimetiques pre-synaptiques dans le sevrage des heroinomanes]. Annales de Medecine Interne 1985;136(5):389-392 [MEDLINE: 86049044]
76. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug and Alcohol Dependence 1988;21(3):253-259 (Pubitemid 18205644)
77. Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. British Journal of Psychiatry 1989;154:348-353 (Pubitemid 19091811)
78. Gowing L, Ali R, White J. Opioid antagonists withminimal sedation for opioid withdrawal. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858]
79. Gowing L, Ali R, White J. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858]
80. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.]
81. Hall W, Darke S. Trends in opiate overdose deaths in Australia 1979-1995. Drug and Alcohol Dependence 1998;52:71-77
82. Jaffe JH, Knapp CM, Ciraulo DA. Opiates: Clinical Aspects. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG editor(s). Substance Abuse: A comprehensive textbook. 3rd Edition. Baltimore: Williams & Wilkins, 1997.
83. Jasinski DR, Johnson RE, Kocher TR. Clonidine in morphine withdrawal: differential effects on signs and symptoms. Archives of General Psychiatry 1985;42(11):1063-1066
84. Kleber HD, Riordan CE. The treatment of narcotic withdrawal: a historical review. Journal of Clinical Psychiatry 1982;43(6):30-34
85. Lipton D, Maranda M. Detoxification from heroin dependency: An overview of method and effectiveness. Advances in Alcohol and Substance Abuse 1983;2(1):31-55.
86. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug & Alcohol Dependence 2001;61(2):195-206. [MEDLINE: 20578850] (Pubitemid 32008534)
87. Mattick RP, Hall W. Are detoxification programmes effective?. Lancet 1996;347:97-100.
88. McCann MJ, Miotto K, Rawson RA, Huber A, Shoptaw S, Ling W. Outpatient non-opioid detoxification for opioid withdrawal. Who is likely to benefit?. American Journal on Addictions 1997;6(3):218-223 [MEDLINE: 97401148] (Pubitemid 27356004)
89. NIH Consensus Development Statement. Effective Medical Treatment of Heroin Addiction. National Institutes of Health 1997, November 17-19
90. Phillips GT, Gossop M, Bradley B. The influence of psychological factors on the opiate withdrawal syndrome. British Journal of Psychiatry 1986;149:235-238 [MEDLINE: 87050435] (Pubitemid 16076260)
91. Preston KL, Bigelow GE. Pharmacological advances in addiction treatment. International Journal of the Addictions 1985;20(6&7): 845-867 [MEDLINE: 86084619]
92. Satel SL, Kosten TR, Schuckit MA, Fischman MW. Should protracted withdrawal from drugs be included in DSM-IV?. American Journal of Psychiatry 1993;150(5):695-704. (Pubitemid 23137673)
93. Sheridan J, Cook C, Strang J. Audit of the in-patient management of opioid withdrawal using lofexidine hydrochloride. Journal of Substance Use 1999;4(1):29-34. [: CINAHL 1999061746] (Pubitemid 29327099)
94. Spencer L, Gregory M. Clonidine transdermal patches for use in outpatient opiate withdrawal. Journal of Substance Abuse Treatment 1989;6:113-117 [MEDLINE: 89311567] (Pubitemid 19150037)
95. Tennant FS, Rawson RA. Guanabenz acetate: a new, long-acting alpha-two adrenergic agonist for opioid withdrawal. NIDA Research Monograph 1984;49:338-343 [MEDLINE: 85012622]
96. Vaillant GE. What can long-term follow-up teach us about relapse and prevention of relapse in addiction?. British Journal of Addiction 1988;83(10):1147-1157 (Pubitemid 19000748)
97. Walsh SL, Strain EC, Bigelow GE. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioiddependent humans. Addiction 2003;98(4):427-439
98. World Drug Report 2007 United Nations Office on Drugs and Crime. World Drug Report 2007. Available from www.unodc.org. * Indicates the major publication for the study